Join
Live feed
·
PRReleasevia Quantisnow
Cara Therapeutics Inc. logo

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

ByQuantisnow·Wall Street's wire, on your screen.
CARA· Cara Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CARA (Cara Therapeutics Inc.) and more on Quantisnow.